{"id":5943,"date":"2011-01-12T10:27:49","date_gmt":"2011-01-12T15:27:49","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=5943"},"modified":"2011-07-19T17:44:39","modified_gmt":"2011-07-19T21:44:39","slug":"large-meta-analysis-explores-cardiovascular-safety-of-nsaids","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/01\/12\/large-meta-analysis-explores-cardiovascular-safety-of-nsaids\/","title":{"rendered":"Large Meta-Analysis Explores Cardiovascular Safety of NSAIDs"},"content":{"rendered":"<p>A large network meta-analysis has found \u201clittle evidence\u201d to suggest that any of the commonly used NSAIDs or COX 2 inhibitors are safe in terms of cardiovascular risk. In\u00a0<a href=\"http:\/\/www.bmj.com\/cgi\/doi\/10.1136\/bmj.c7086\">a paper published in\u00a0<em>BMJ<\/em><\/a>, Sven Trelle and colleagues analyzed data from 31 trials in which patients receiving an NSAID were compared to another NSAID or placebo. Rofecoxib was associated with the highest risk of MI while naproxen appeared to be the safest of the agents studied. The authors concluded that \u201coptions for the treatment of chronic musculoskeletal pain are limited and patients and clinicians need to be aware that cardiovascular risk needs to be taken into account when prescribing.\u201d<\/p>\n<p>In\u00a0<a href=\"http:\/\/www.bmj.com\/cgi\/doi\/10.1136\/bmj.c6618\">an accompanying editorial<\/a>, Wayne Ray writes that the limitations of the meta-analysis mean the results \u201cshould be interpreted with caution.\u201d Although naproxen appears to be the safest agent it may require the concomitant use of a gastroprotective agent. Ray writes that \u201cdrugs for symptomatic relief must be evaluated with regard to the target symptoms as well as less frequent yet serious adverse effects. NSAIDs are not an ideal treatment with respect to efficacy or safety.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A large network meta-analysis has found \u201clittle evidence\u201d to suggest that any of the commonly used NSAIDs or COX 2 inhibitors are safe in terms of cardiovascular risk. In\u00a0a paper published in\u00a0BMJ, Sven Trelle and colleagues analyzed data from 31 trials in which patients receiving an NSAID were compared to another NSAID or placebo. Rofecoxib [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[652,651,650],"class_list":["post-5943","post","type-post","status-publish","format-standard","hentry","category-general","tag-analgesics","tag-cox-2-inhibitors","tag-nsaids"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=5943"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5943\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=5943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=5943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=5943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}